Black checkmark with a sparkle and a curved line underneath on a white background.
Company

MapLight Therapeutics, Inc.

Ticker
MPLT
Sector
Industry
Report date
November 16, 2026
Valye AI Score

94

Very high visibility
Recent developments
Recent developments summary

Recent developments include a $150 million PIPE financing to fund the CNS pipeline, mixed Phase 2 schizophrenia trial results with some cognitive endpoints met, insider buying activity, and a notable stock price decline over a four-week period.

Recent developments:
  • MapLight raised $150 million through a PIPE financing to support its CNS pipeline development [N2].
  • The company reported mixed results from its Phase 2 ZEPHYR schizophrenia trial, with some key cognitive endpoints achieved, though shares declined following the announcement [N8].
  • Insider buying activity was reported in July 2026, indicating management confidence [N4].
  • The stock price declined 34.8% over four weeks as of October 2026, with analysis suggesting potential for a turnaround [N1].
  • Multiple Phase 2 readouts are anticipated in 2026, reflecting ongoing clinical progress [N3].
Overview

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to develop circuit-specific pharmacotherapies targeting neural circuits linked to CNS disorders. Its lead product candidate, ML-007C-MA, combines an M1/M4 muscarinic agonist with a peripherally acting anticholinergic to treat schizophrenia and Alzheimer's disease psychosis. The company has conducted multiple Phase 1 trials and is currently running Phase 2 trials (ZEPHYR for schizophrenia and VISTA for ADP). ML-007C-MA received FDA Fast Track designation for ADP. MapLight has no current product revenue and finances operations through equity offerings and grants. The company maintains strong liquidity with cash, equivalents, and short-term investments totaling approximately $284 million as of September 30, 2026. It leases facilities in California and Massachusetts and has acquired key intellectual property through asset purchases and licensing agreements.

Executive summary

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, primarily schizophrenia and Alzheimer's disease psychosis. The company’s lead candidate, ML-007C-MA, is in Phase 2 clinical trials with topline results anticipated in 2026 and 2027. MapLight has incurred significant net losses and operates with strong liquidity, supported by recent capital raises including a $150 million PIPE financing. The company faces typical clinical-stage biotech risks including clinical development uncertainty, regulatory approval challenges, and funding needs. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for MPLT

Bull case model:

MapLight’s lead candidate ML-007C-MA has demonstrated potential efficacy and tolerability advantages in early clinical trials, with FDA Fast Track designation supporting regulatory engagement. The company’s discovery platform targeting neural circuits offers a novel approach to CNS disorders. Recent capital raises provide funding to advance multiple Phase 2 trials, and positive clinical readouts could validate the therapeutic approach and support further development and commercialization.

Bear case model:

MapLight faces significant risks typical of clinical-stage biopharmaceutical companies, including the inherent unpredictability of clinical trial outcomes, regulatory hurdles, and the need for substantial additional funding. Mixed Phase 2 trial results and recent stock price declines highlight market uncertainty. Failure to achieve regulatory approval or secure sufficient capital could materially impact operations. The company currently has no product revenue and continues to incur significant net losses.

Moat:

MapLight’s moat is based on its proprietary discovery platform targeting neural circuits causally linked to CNS disorders and its lead candidate ML-007C-MA, which combines targeted muscarinic receptor activation with mitigation of peripheral side effects. The company’s intellectual property portfolio includes assets acquired from NeuroSolis and licensing arrangements. Its focus on circuit-specific pharmacotherapies addresses a significant unmet medical need in CNS disorders, potentially differentiating its product candidates. However, as a clinical-stage biotech, the moat is contingent on successful clinical development and regulatory approval.

Risks overview
Risks summary
The biggest risks for MapLight Therapeutics are the uncertainties in clinical development and regulatory approval processes, combined with the need for ongoing funding to sustain operations and advance its pipeline.
Risks details:

• Clinical Development Risk: The success of MapLight’s product candidates depends on the timely and successful completion of clinical trials, which are inherently uncertain and costly.
• Regulatory Approval Risk: Obtaining regulatory approval from the FDA or other authorities involves complex processes and there is no assurance of approval for any product candidate.
• Funding Risk: MapLight requires substantial additional funding to continue operations and advance clinical programs; inability to raise capital on acceptable terms could adversely affect the business.
• Operational Risk: As a public company, MapLight faces increased legal, accounting, and compliance costs, and must manage growth and infrastructure expansion effectively.

FINAL FORECAST FOR MPLT

Final take one line
MapLight Therapeutics is a clinical-stage biotech with a focused CNS pipeline, strong liquidity, and detailed public disclosures, facing typical development and funding risks.
Final take 12 to 24 month view

Business trends: Advancement of Phase 2 clinical trials for schizophrenia and Alzheimer's disease psychosis; ongoing capital raises to fund pipeline development.
Execution milestones: Reporting of topline Phase 2 trial results in 2026 and 2027; continued clinical and regulatory progress including FDA Fast Track designation.
Key risks: Clinical trial outcome uncertainty, regulatory approval challenges, need for substantial additional funding, and operational risks as a public company.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

94
LLM visibility overview
LLM Visibility known facts
  • MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) disorders, including schizophrenia and Alzheimer's disease psychosis (ADP).
  • The company was founded by leaders in psychiatry and neuroscience to develop circuit-specific pharmacotherapies targeting neural circuits causally linked to disease.
  • Their lead product candidate is ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist co-formulated with a peripherally acting anticholinergic, designed to treat schizophrenia and ADP.
  • ML-007C-MA aims to activate M1 and M4 muscarinic receptors centrally to drive efficacy while mitigating peripheral cholinergic side effects.
  • ML-007C-MA has undergone four Phase 1 trials with 270 healthy participants and over 1,500 doses administered.
  • The company is conducting the ZEPHYR Phase 2 trial for schizophrenia with a target enrollment of 300 participants and topline results anticipated in Q3 2026.
  • The VISTA Phase 2 trial for ADP is ongoing with topline results anticipated in the second half of 2027.
  • ML-007C-MA received FDA Fast Track designation in December 2025 for treatment of hallucinations and delusions associated with ADP.
  • MapLight has incurred significant net losses since inception, with net losses of $161.2 million in 2025 and $77.6 million in 2024, and an accumulated deficit of $360.5 million as of December 31, 2025.
  • The company has financed operations primarily through sales of redeemable convertible preferred stock, research grants, IPO proceeds, and a $150 million PIPE financing in August 2026.
  • As of September 30, 2026, MapLight held $55.6 million in cash and equivalents and $228.5 million in short-term investments, with a current ratio of 9.53 and cash ratio of 9.19, indicating strong liquidity.
  • The company leases office and laboratory space in Redwood City, California, and Burlington, Massachusetts, with leases extending to 2029 and 2031.
  • MapLight acquired proprietary M1/M4 agonist molecules and associated intellectual property from NeuroSolis in 2020, with milestone payments and equity issuance contingent on development progress.
  • The company transferred certain intellectual property rights to Stellaromics in 2023 in exchange for equity and continued usage rights.
  • Research and development expenses include personnel costs, CRO fees, clinical trial costs, and facility expenses, and are expected to increase as clinical programs advance.
  • MapLight has not generated any revenue to date and does not anticipate revenue from product sales in the foreseeable future.
  • The company faces risks including the unpredictability of clinical development, regulatory approval challenges, funding requirements, and operational risks as a public company.
  • Recent news highlights include the $150 million PIPE financing to fund the CNS pipeline, mixed Phase 2 schizophrenia trial results with some cognitive endpoints met, and insider buying activity.
  • The stock price declined 34.8% over four weeks as of October 2026, with some commentary suggesting potential for turnaround.
  • The company reported multiple Phase 2 readouts anticipated in 2026 and has received FDA Fast Track status for its Alzheimer's psychosis drug.
  • MapLight's schizophrenia drug hit a Phase II primary endpoint in July 2026, though shares fell following mixed trial results.
Sources
Sources - Context summary

Generated 2026-11-16

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-26 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-10-14 | www.nasdaq.com | Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround | https://www.nasdaq.com/articles/down-348-4-weeks-heres-why-maplight-therapeutics-inc-mplt-looks-ripe-turnaround
  • N2 | 2026-08-13 | www.nasdaq.com | MapLight Raises $150 M PIPE To Fund CNS Pipeline | https://www.nasdaq.com/articles/maplight-raises-150-m-pipe-fund-cns-pipeline
  • N3 | 2026-07-31 | www.nasdaq.com | Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals | https://www.nasdaq.com/articles/weekly-buzz-cipla-vtrs-win-fda-nod-bsx-cuts-jobs-argx-snaps-fbrx-jnj-gsk-strike-deals
  • N4 | 2026-07-29 | www.nasdaq.com | Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend? | https://www.nasdaq.com/articles/top-biotech-gainers-knsa-soars-q2-results-trib-opk-watch-mplt-mend
  • N5 | 2026-07-28 | www.nasdaq.com | Stocks Settle Mixed as AI Angst Offsets Easing Geopolitical Tensions | https://www.nasdaq.com/articles/stocks-settle-mixed-ai-angst-offsets-easing-geopolitical-tensions
  • N6 | 2026-07-27 | www.nasdaq.com | Stocks Fall from Early Highs as Chipmakers Retreat | https://www.nasdaq.com/articles/stocks-fall-early-highs-chipmakers-retreat
  • N7 | 2026-07-27 | www.nasdaq.com | Oversold Conditions For Maplight Therapeutics (MPLT) | https://www.nasdaq.com/articles/oversold-conditions-maplight-therapeutics-mplt
  • N8 | 2026-07-27 | www.nasdaq.com | Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint | https://www.nasdaq.com/articles/maplight-therapeutics-schizophrenia-drug-hits-phase-ii-primary-endpoint
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine